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Themost common formofmaturity-onset diabetes of the young (MODY) is caused bymutations in the hepatocyte nuclear factor 1A
(HNF1A) gene. However, mostHNF1Amutation-carriers are initially misdiagnosed with type 1 (T1DM) or type 2 (T2DM) diabetes
mellitus; hence, they often receive nonoptimal treatment. The aim of our study was to test newly proposed clinical criteria for the
identification of HNF1AMODY in patients with a diagnosis of T1DM or T2DM. To achieve this, the following criteria to preselect
patients for screening were used: for T1DM: TDIR (total daily insulin requirement) > 0.3 IU of insulin/kg and the percentage of
basal insulin > 30% of TDIR; for T2DM: sulphonylurea- (SU-) based oral treatment (monotherapy or combined with Metformin)
> 15 years and BMI < 30 kg/m2. We reviewed the clinical data of 140 patients with T1DM and 524 clinically diagnosed with T2DM.
On the basis of these criteria, we found aHNF1Amutation in 1 out of 2 individuals with a diagnosis of T1DM and 1 out of 11 selected
individuals with a diagnosis of T2DM.We believe that the simplicity of the proposed criteria might prove useful in clinical practice,
as an alternative to more time-consuming classical diagnostic techniques.
1. Introduction
The most common form of maturity-onset diabetes of the
young (MODY) is caused by mutations in the hepatocyte
nuclear factor 1A (HNF1A) gene [1, 2]. It is well established
that patientswithHNF1AMODYare very sensitive to sulpho-
nylureas (SU) and can be taken off insulin treatment after
the proper molecular diagnosis [1, 2]. However, most patients
with this type of monogenic diabetes are initially misdiag-
nosed with either type 1 (T1DM) or type 2 (T2DM) diabetes
mellitus; hence, they often receive nonoptimal treatment
[3]. The effective selection of “T1DM” and “T2DM” patients
for molecular testing for the HNF1A MODY mutation does
present some challenges. It is usually based on clinical criteria
suggested by Ellard et al. [2]. ForHNF1AMODY they include
young-onset diabetes, being non-insulin-dependent outside
the normal honeymoon period, family history of diabetes,
the absence of pancreatic islet autoantibodies, glycosuria
at blood glucose levels <10mmol/L, marked sensitivity to
sulfonylureas, and no marked obesity or evidence of insulin
resistance [2].
However, a recent retrospective analysis of a large pedi-
atric cohort showed that only a small portion of MODY
subjects were properly diagnosed in spite of having negative
pancreatic autoantibodies, preserved endogenous insulin
production, or strong family history of diabetes in multiple
generations [4]. Biochemical biomarkers are also of limited
value [2]. High sensitivity CRP (hsCRP) seemed to be one of
the most promising. However recent data suggest that while
being a good marker to make differential diagnosis between
HNF1A MODY and T2DM, it brings no additional value
to differentiate between patients with established diagnosis
of HNF1A MODY and individuals with a clinical history
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suggestive of HNF1A MODY, but not confirmed genetically
[5].
Aim of the Study. The aim of our study was to test newly
proposed clinical criteria for selecting patients with an initial
clinical diagnosis of either T1DM or T2DM for HNF1A
MODYmolecular testing.
2. Material and Methods
Subjects diagnosed with either T1DM or T2DM were pre-
selected and ascertained as previously defined [6, 7]. All
patients underwent molecular testing at the Department of
Metabolic Diseases, Medical College, Jagiellonian University,
Krakow, Poland [8].The studywas approved by the Bioethical
Committee of Jagiellonian University.
2.1. Differential Diagnosis: T1DM versus HNF1A MODY. To
establish the clinical criteria for preselecting individuals
diagnosed with T1DM for HNF1Amolecular testing, we per-
formed a retrospective analysis of patients with an established
HNF1A MODY diagnosis (131 patients, 46 males and 85
females). We found that before genetic testing 40 patients
had been diagnosed and treated as T1DM patients. Based
on the characteristics of these 40 misdiagnosed patients,
we established new criteria for further molecular testing for
HNF1A mutations. We subsequently reviewed the clinical
data of 140 patients diagnosed with T1DM to preselect indi-
viduals meeting our newly established criteria. The diagnosis
of T1DM was based on clinical criteria; autoantibodies were
not determined.
3. Results
3.1. T1DM versus HNF1A. Analysis of the clinical data of 40
HNF1A mutation-carriers, who had been treated as T1DM
before MODY diagnosis, showed that, on average, their total
daily insulin dose was 0.28 j/kg± 0.11 j (range: 0.19–0.34 j/kg).
The data concerning the percentage of basal insulin versus
TDIR was available for only six individuals and its median
was equal to 32% ± 6 j (range: 26–33%). On the basis of these
data, we established the cut-off point for potential MODY at
0.3 IU of insulin per kg and the percentage of basal insulin
being >30% of TDIR. As reported earlier, the mean insulin
requirement per kg of body mass for T1DM patients was
0.69 IU/kg, whereas the percentage of basal insulinwas 42.6%
[9].
Of the 140 patients with an initial T1DM diagnosis,
based on the aforementioned criteria, two individuals were
selected for further molecular testing by Sanger sequencing.
A previously described diabetes-related mutation in exon 4
(P291fsinsC) was found in one individual [1]. Interestingly,
the maternal family history of this patient was negative for
diabetes; however, no data on the paternal branch of the
family was available.
3.2. T2DM versus HNF1A. To select subjects from the T2DM
cohort for HNF1A gene sequencing, the following criteria
were used: SU-based oral treatment (SU in monotherapy
or combined with Metformin) for >15 years and a body
mass index < 30 kg/m2. We analyzed the medical records
of 524 patients clinically diagnosed with T2DM to preselect
individuals for genetic screening for the HNF1A MODY
mutation. Based on suggested clinical criteria, we selected
14 subjects from the T2DM patient cohort; however, only 11
were available for testing (9% of selected T2DMcases). In one
of these 11 patients, a previously undescribed mutation was
identified: a deletion of amino acids 1283–1309 of theHNF1A
gene. Since this deletion is relatively large (1.3% of exon 7) and
is located in the carboxyl-terminal transactivation domain,
which is crucial forHNF1A function, it is highly probably that
this is a causative variant of diabetes in this subject [10]. Ret-
rospective analysis of the clinical data of this patient revealed
positive family history for diabetes, which is suggestive of
an autosomal-dominant mode of inheritance. Unfortunately,
other family members were not available for segregation
analysis.
4. Discussion
Misdiagnosis of monogenic diabetes has an impact both on
glycemic control and on quality of life of affected individ-
uals [1]. There is hope that, with improved accessibility of
next generation sequencing (NGS), the number of patients
correctly diagnosed with MODY will increase substantially;
however, at this point in time, access to this high-throughput
methodology is still limited [11]. Here, we propose new
clinical criteria for preselection of patients initially diagnosed
with either T1DM or T2DM for genetic testing for the iden-
tification of mutations in HNF1A. As there were some earlier
reports suggesting that de novo MODY mutations might be
more frequent than previously considered, we did not include
family history as part of our criteria [12]. Of note, in our study,
the HNF1A mutation-carrier identified among patients with
a clinical diagnosis of T1DMwas indeed negative for diabetes
in his families. Interestingly, in a recent study involving
patients with an initial diagnosis of T1DM, which used
three traditional criteria (negative pancreatic autoantibodies,
sustained endogenous insulin production, and strong family
history of diabetes in multiple generations), only one of
58 patients was identified to be a HNF1A mutation-carrier
[13].
As for differential diagnosis between T2DM and HNF1A
MODY, the success rate based on our proposed preselection
criteria was relatively small (1 out of 11). This may mean that
clinical criteria to identify HNF1A mutation-carriers should
be probably more restrictive. Testing them would require
much larger group of patients to come up with sufficient
number of individualsmeeting those narrow,more restrictive
criteria.
In general, due to relatively small sample size, our study
should be considered as a preliminary one. Furthermore,
the assessment of diagnostic sensitivity and specificity of our
criteria would require sequencing, preferentially NGS, to be
performed in the entire initial cohort of T1DM and T2DM
subjects.
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5. Conclusions
We believe that criteria proposed in the present study might
be useful for clinicians, as an alternative to classical criteria,
to select T1DM and T2DM patients who should undergo
molecular testing for mutations in HNF1A. Though our
criteria show potential, further research and validation are
required.
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